Heregulin regulates prolactinoma gene expression.

To investigate the role of p185(her2/neu)/ErbB3 signaling in pituitary tumor function, we examined these receptors in human prolactinomas. Immunofluorescent p185(her2/neu) was detected in almost all (seven of eight), and ErbB3 expression in a subset (four of eight) of tumors (seven adenomas and one carcinoma). Quantitative PCR also showed abundant ErbB3 mRNA in tumor specimens derived from a rarely encountered prolactin-cell carcinoma. Activation of p185(c-neu)/ErbB3 signaling with heregulin, the ErbB3 ligand, in rat lacto-somatotroph (GH4C1) tumor cells specifically induced prolactin (PRL) mRNA expression approximately 5-fold and PRL secretion approximately 4-fold, whereas growth hormone expression was unchanged. Heregulin (6 nmol/L) induced tyrosine phosphorylation and ErbB3 and p185(c-neu) heterodimerization, with subsequent activation of intracellular ERK and Akt. The Akt signal was specific to ErbB3 activation by heregulin, and was not observed in response to epidermal growth factor activation of epidermal growth factor receptor. Gefitinib, the tyrosine kinase inhibitor, suppressed heregulin-mediated p185(c-neu)/ErbB3 signaling to PRL. Heregulin induction of PRL was also abrogated by transfecting cells with short interfering RNA directed against ErbB3. Pharmacologic inhibition of heregulin-induced phosphoinositide-3-kinase/Akt (with LY294002) and ERK (with U0126) signaling, as well as short interfering RNA-mediated mitogen-activated protein kinase-1 down-regulation, showed ERK signaling as the primary transducer of heregulin signaling to PRL. These results show ErbB3 expression in human prolactinomas and a novel ErbB3-mediated mechanism for PRL regulation in experimental lactotroph tumors. Targeted inhibition of up-regulated p185(c-neu)/ErbB3 activity could be useful for the treatment of aggressive prolactinomas resistant to conventional therapy.

[1]  S. Kansra,et al.  Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs. , 2009, Endocrinology.

[2]  S. Melmed,et al.  Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. , 2008, Cancer research.

[3]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[4]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[5]  Qiang Wang,et al.  ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.

[6]  M. Zhou,et al.  Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners. , 2007, Cellular signalling.

[7]  A. Tischler,et al.  Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists , 2007, Pituitary.

[8]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[9]  E. Reiter,et al.  Growth hormone , 1993 .

[10]  K. Kovacs,et al.  Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. , 2007, Human pathology.

[11]  P. Kelly,et al.  Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[12]  J. Schlechte,et al.  Management of resistant prolactinomas , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[13]  J. Romijn,et al.  Malignant prolactinoma: case report and review of the literature. , 2006, European journal of endocrinology.

[14]  M. Papotti,et al.  Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. , 2006, European journal of endocrinology.

[15]  P. Cappabianca,et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas , 2006, Clinical endocrinology.

[16]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[17]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[18]  F. Schmitt,et al.  Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. , 2006, Arquivos de neuro-psiquiatria.

[19]  G. Fuller,et al.  Pineal Cyst Apoplexy: Case Report and Review of the Literature , 2005, Neurosurgery.

[20]  M. Korbonits,et al.  Enhanced protein kinase B/Akt signalling in pituitary tumours. , 2005, Endocrine-related cancer.

[21]  M. Kuwano,et al.  HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. , 2005, Cancer research.

[22]  M. Buchfelder,et al.  Diagnosis and Management of Pituitary Carcinomas , 2005 .

[23]  M. Buchfelder,et al.  Clinical review: Diagnosis and management of pituitary carcinomas. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  B. Scheithauer,et al.  Pituitary Carcinoma: A Clinicopathological Review. , 2005, Neurosurgery.

[25]  T. Arzberger,et al.  Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. , 2004, The Journal of endocrinology.

[26]  B. Scheithauer,et al.  Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas , 2004, Modern Pathology.

[27]  D. Lüdecke,et al.  Proliferation Markers in Different Types of Clinically Non-Secreting Pituitary Adenomas , 1999, Pituitary.

[28]  S. Melmed.  Mechanisms for pituitary tumorigenesis: the plastic pituitary. , 2003, The Journal of clinical investigation.

[29]  B. Scheithauer,et al.  Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases. , 2003, Journal of neurosurgery.

[30]  J. Baselga,et al.  ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  A. Gutierrez-Hartmann,et al.  PRL-releasing peptide stimulation of PRL gene transcription--enter AKT. , 2002, Endocrinology.

[32]  A. Gutierrez-Hartmann,et al.  Editorial: PRL-Releasing Peptide Stimulation of PRL Gene Transcription-Enter AKT. , 2002, Endocrinology.

[33]  R. Maurer,et al.  Thyrotropin-releasing hormone stimulates phosphorylation of the epidermal growth factor receptor in GH3 pituitary cells. , 2000, Molecular endocrinology.

[34]  G. Cantore,et al.  Epidermal growth factor binding sites in human pituitary macroadenomas. , 1998, The Journal of endocrinology.

[35]  M. Kayath,et al.  Adrenocorticotropin-producing pituitary carcinoma with expression ofc-erbB-2 and high PCNA index: A comparative study with pituitary adenomas and normal pituitary tissues , 1998, Endocrine pathology.

[36]  S. Asa,et al.  The c‐erbB‐2/neu proto‐oncogene in human pituitary tumours , 1997, Clinical endocrinology.

[37]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[38]  S. Asa,et al.  Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. , 1996, The Journal of clinical endocrinology and metabolism.

[39]  K. Kovacs,et al.  Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: An immunocytochemical study , 1996, Endocrine pathology.

[40]  A. Gutierrez-Hartmann,et al.  Epidermal growth factor and Ras regulate gene expression in GH4 pituitary cells by separate, antagonistic signal transduction pathways , 1995, Molecular and cellular biology.

[41]  Kristina J. Liu,et al.  Report of two cases , 1995 .

[42]  S. Asa,et al.  Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. , 1995, Endocrinology.

[43]  P. Stewart,et al.  Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. , 1994, Endocrinology.

[44]  A. Gutierrez-Hartmann,et al.  Identification of the functional components of the Ras signaling pathway regulating pituitary cell-specific gene expression , 1994, Molecular and cellular biology.

[45]  S. George,et al.  Dopamine receptor activation inhibits estrogen-stimulated transforming growth factor-alpha gene expression and growth in anterior pituitary, but not in uterus. , 1992, Endocrinology.

[46]  B. Scheithauer,et al.  Presence of growth factors in human pituitary. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[47]  D. Weiner,et al.  Differential regulation of oncogenic and cellular p185 by serine/threonine kinases. , 1989, DNA.

[48]  E. Moyse,et al.  Receptors and neurohormones in human pituitary adenomas. , 1989, Hormone research.

[49]  F. Peillon,et al.  Epidermal growth factor-binding sites, present in normal human and rat pituitaries, are absent in human pituitary adenomas. , 1987, The Journal of clinical endocrinology and metabolism.

[50]  R. Weinberg,et al.  Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene , 1984, Nature.

[51]  G. Lemke,et al.  Identification and purification of glial growth factor , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[52]  J. Martial,et al.  Absence of high affinity dopamine receptor in GH3 cells: a prolactin-secreting clone resistant to the inhibitory action of dopamine. , 1980, Endocrinology.